Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma

TUB-040 is a next-generation NaPi2b-targeting…

Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease

Bagsværd, Denmark, and Hannover, Germany,…

Fund+ Portfolio Company Tubulis Closes Upsized EUR 128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Financing round co-led by EQT…

Confo Therapeutics Appoints Dieter Weinand, Former CEO of Bayer Pharmaceuticals, as Independent Chairman

Ghent, Belgium – August 29,…

Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

• Collaboration to make use…

Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy

US trial with leriglitazone to…

Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b

- CTx-PDE6b demonstrated clinically meaningful…

ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors

• Leading medical oncologist and…

Indigo Appoints Dr. Arun Venkatasubramanian as Chief Technology Officer

Arun is an award-winning engineer…

Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)

Initial evidence of disease stabilization…